These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962 [TBL] [Abstract][Full Text] [Related]
3. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Sarafidis PA; Bakris GL Kidney Int; 2006 Oct; 70(7):1223-33. PubMed ID: 16883325 [TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts. Zhang GY; Cheng T; Zheng MH; Yi CG; Pan H; Li ZJ; Chen XL; Yu Q; Jiang LF; Zhou FY; Li XY; Yang JQ; Chu TG; Gao WY J Plast Reconstr Aesthet Surg; 2010 Jul; 63(7):1209-16. PubMed ID: 19617014 [TBL] [Abstract][Full Text] [Related]
5. Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-gamma activation in +db/+m and +db/+db mice. Seto SW; Lam TY; Leung GP; Au AL; Ngai SM; Chan SW; Kwan YW Eur J Pharmacol; 2007 Oct; 572(1):40-8. PubMed ID: 17603034 [TBL] [Abstract][Full Text] [Related]
6. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. Zhang GY; Yi CG; Li X; Ma B; Li ZJ; Chen XL; Guo SZ; Gao WY Br J Dermatol; 2009 Apr; 160(4):762-70. PubMed ID: 19120328 [TBL] [Abstract][Full Text] [Related]
7. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596 [TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones--tools for the research of metabolic syndrome X. Komers R; Vrána A Physiol Res; 1998; 47(4):215-25. PubMed ID: 9803467 [TBL] [Abstract][Full Text] [Related]
9. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells. Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790 [TBL] [Abstract][Full Text] [Related]
10. PPARgamma agonists: killing two birds with one stone? Ritz E J Hypertens; 2004 Sep; 22(9):1673-4. PubMed ID: 15311092 [No Abstract] [Full Text] [Related]
11. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Gaikwad AB; Viswanad B; Ramarao P Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046 [TBL] [Abstract][Full Text] [Related]